Ministry of Higher Education

and Scientific Research

University of Diyala

College of Medicine

Article review of:

Cystic fibrosis

Submitted to the Council of the College of Medicine, Diyala University, In Partial Fulfillment of Requirements for the Bachelor Degree in medicine and general surgery.

Submitted by

Sajjad hafedh abdullah

Supervised by

Assist.Prof Aseel Jasim Muhammad

2021/2022

Acknowledgment

Allah, my lord, God, you were always with me on my journey, and I can't thank you enough for everything you provided me.

I owe a great deal of gratitude to the kind people who assisted and supported me in completing this project.

My heartfelt gratitude goes to (Assist.Prof Aseel Jasim Muhammad), my educator and supervisor, for leading me through the article by correcting errors and providing helpful insights into a variety of scientific facts and literature. I wish her the best of luck and success in her career and future.

Table of contents

REFERENCES | **21**

Abstract

"Cystic fibrosis is a congenital autosomal recessive illness resulting from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The chromosomal deficiency was initially discovered 3 decades previously, and great progress has been made since then in our knowledge of how CFTR mutations cause illness and how to treat it. CFTR is a transmembrane protein that transfers ions across epithelial cell membranes. Although CFTR deficiency affects numerous organs, lung illness accounts for the great majority of morbidity and death in cystic fibrosis patients. Early diagnostics, neonatal screening, and new treatment algorithms are altering the disease's incidence and prevalence. Until relatively recent times, the level of care in cystic fibrosis treatment centered on preventing and treating disease complications; now, innovative treatment methodologies specifically targeting the ion channel deformity are becoming obtainable, and it will be critical to assess how these treatments impact the disease process and patient quality of life."

Introduction

Since ancient times, children all around the world have been afflicted with cystic fibrosis, which causes premature death. In medieval Europe, these children were thought to be cursed by witches and doomed. The renowned curse is, unfortunately, to the infant who tastes salty from a kiss on the brow, because he is cursed and will die shortly. Salty skin was an indication of illness with no known cause or remedy.[1]

Cystic fibrosis was poorly understood until recently. Until (1949), Lowe et al. assumed that cystic fibrosis was caused by a genetic abnormality with an autosomal recessive genetic basis.[1]

According to research, cystic fibrosis, also known as mucoviscidosis, is a multisystemic and life-shortening autosomal recessive genetic condition affecting the exocrine glands. The presence of excessive amounts of salt in the sweat of children with cystic fibrosis showed a problem with electrolyte transport from the sweat gland.[1]

A mutation in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene that regulates the expression of chloride channels protein (transmits ions through the apical membrane of epithelial cells all over the body), which adjusts the action of other sodium and chloride channels but also has numerous different functions, such as suppression of sodium transport and bicarbonate secretion, that are important for the pathophysiology of (CFTR) dysfunction and deficiency. This channel extends over the

apical membrane of the reproductive, digestive, respiratory, sweat, and mucus-producing epithelial cells.[2]

Mutations in (CFTR) are categorized into classes according to their functional implications; those relevant for loss of (CFTR) expression on the cell surface or loss of function are often large mutations linked with a phenotype of both lung and pancreatic illness. Even though residual (CFTR) function mutations are frequently accompanied by intact pancreatic function, some individuals exhibit solitary organ symptoms, such as a congenital bilateral loss of the vas deferens in the male reproductive tract. As multi-organ presentations of bronchiectasis, pancreatitis, or sinusitis, other types of mutations have also been documented.[2][3]

The landmark discovery of the cystic fibrosis gene defect in (1989) brought in a leading understanding of the disease's pathogenesis, however, this information has only recently been pushed to targeted therapies that address the relevant cellular abnormality.[11]

Over the last two decades, significant advancements in all facets of the condition have indeed been made, and luckily, the prognosis of people with cystic fibrosis is steadily improving.

There are about (70,000 cases) globally, with approximately (1000 new cases) reported annually. predominantly appear in the population of European origin (1:2000-3000), whereas it is three to four times less prevalent in the demographic groups of other ancestors, but least among Asian Americans (1:30,000 newborns). Caucasians have a (1:25-30) prevalence of heterozygous carriers of the afflicted gene, making it the most prevalent hereditary illness that shortens life.[4]

Ever since (the 1940s), the development and use of a plethora of symptomatic treatments and extensive prophylactic treatment regimens have increased the median predicted survival from a few months after diagnosis to (38 years of age) for the cohort in the US cystic fibrosis Foundation Patient Registry that carried on in (2008 to 2012) and (34 to 44 years of age) for the cohort in the United Kingdom cystic fibrosis Registry that carried on in (2009 to 2013). In (2012), the median age of death among people with cystic fibrosis tracked by patient registries in the United States and the United Kingdom was (27 to 28 years). It is now recognized that therapies addressing the causative (CFTR) deficiency throughout the body's systems have the potential to improve long-term results.[8]

Because of the multiorgan disorders that can emerge in cystic fibrosis patients, commencing symptomatic and preventative medications early in life, beginning with newborn screening, has been demonstrated to enhance outcomes when compared to later therapy initiation related to a later diagnosis.

Interventions that address the causative (CFTR) deficiency before significant disease progression have a high likelihood of avoiding additional tissue damage and enabling optimal health maintenance and normal-like function. The best moment to intervene with therapies is when problems and cumulative harm start to develop. Although advances in care for individuals with cystic fibrosis have

resulted in significant advances in survival, persons with cystic fibrosis still experience terrible symptoms and die prematurely due to multiple organ failures.[3]

It has long been recognized that neonates with cystic fibrosis can suffer from severe pancreatic insufficiency as well as gastrointestinal problems. While the most recent studies and careful analyses have begun to demonstrate that respiratory system defects associated with early disease development can be identified quite early.[3][6][7]

We still don't have a thorough evaluation of the ages of initial illness manifestation and development across organ systems, which is a significant information gap, even though disease progression is unique to each individual. As a result, this research concentrated on the respiratory and digestive systems to identify the key symptoms and causes of mortality linked with these two body systems.

Epidemiology

The epidemiology of cystic fibrosis has been altered by changes in diagnostic criteria and procedures, as well as advances in therapeutic outcomes. Estimates of illness incidence in people of Northern European heritage range from (1 in 3,000 to 1 in 1,400 live births), with Ireland having the highest incidence at (1 in 1,400 live births).[2]

The incidence varies by race and ethnicity; only (1 in 4,000 to 10,000 Latin Americans) and (1 in 15,000 to 20,000 African Americans) have cystic fibrosis, with even lower percentages among Asians. These figures are based on information from Western nations; however, epidemiological statistics for major sections of the world, such as the Middle East, Asia, and Africa, are lacking.[1][2]

The advent of prenatal genetic screening in Western nations appears to be associated with a decrease in some countries' occurrence. Even though the incidence is dropping, statistics from registries indicate that the prevalence is growing due to increases in survival. Recent studies in the United States show that cystic fibrosis survival improved at a rate of 1.8 percent per year (95 percent CI, 0.5–2.7 percent) from (2000 to 2010) and that the projected median survival of children born today is 56 years (95 percent CI, 54–58 years) if the mortality rate continues to fall at this rate. However, the median mortality age remains in the mid-twenties to the early thirties. These findings are consistent with previous findings from the United Kingdom.[2]

In several nations, nationwide screening test has shifted the diagnosis of cystic fibrosis earlier in life, which is linked with increased survival. In (2010), newborn screening identified more than half (58%) of individuals with cystic fibrosis in the United States, comparable to (only 8%) of those recognized (in 2000). Numerous nations currently indicate that more than half of their cystic fibrosis population is beyond the age of 18. Not only has the affected person aged, but a growing number of individuals with mild phenotypes of cystic fibrosis have been detected as an outcome of breakthroughs in CFTR mutation genotyping, which correlates to but does not entirely explain the rise in lifespan. in patients (aged 40 and over) who were diagnosed after the (age of 15), the

median age of diagnosis has been reported to be 48.8 years (ranging, from 24 to 72.8 years). These people are far more likely to have a nonclassical phenotype. Even when in patients with severe lung disease, survival is rising.[2]

Pathophysiology

Cystic fibrosis is caused by CFTR gene mutations on chromosome 7's long arm. Over (1,500 genetic mutations) associated with the incidence of this illness have been detected to date. CFTR gene mutation has been revealed in (70-80 percent of patients), followed by phenylalanine deletion at location 508 (F508) in fifty percent of homozygous sufferers and (25-30 percent) in persons with additional genetic issues.[2]

The CFTR gene is a one-of-a-kind member of the ATP-binding cassette (ABC) or traffic ATPase family of genes with an actively phosphorylated regulatory domain. CFTR is largely an apical anion channel of chloride and bicarbonate, instead of an active pump. Similar to other ABC protein relatives, it has two nucleotide-binding domains (NBDs) encoding regions capable of binding and hydrolyzing ATP (Walker A and motif B) and membrane-spanning domains that operate as the ion channel hole across the cellular membranes.[2]

CFTR mutations can decrease channel number, function, or both, and can range in intensity and emerge via a wide range of biological pathways. While genetic moderators and environmental variables have a role in the etiology, the comparative severity and wholeness of each genetic flaw have a considerable impact on the symptoms and severity of illness (that is, the cystic fibrosis phenotype).[2]

The existence of at least a single partly active CFTR allele can greatly enhance clinical outcomes; this is also evidenced by lower sweat chloride concentrations or a high probability of pancreatic sufficiency in contrast to those who have no functioning CFTR. Anomalous types of cystic fibrosis can start to appear moderate or variant mutations are present, or when a single mutation has an adequate function, such as congenital loss of the vas deferens, idiopathic pancreatitis, or extremely late-onset respiratory illness without any other cystic fibrosis symptoms. [2]

A comprehensive inventory of the phenotypes discovered in described individuals is available online and can give diagnostic and prognostic information to care delivery. Although categorizing CFTR alleles into molecular groups aid in our awareness of the underlying abnormality, it is now obvious that many mutations exhibit more than one trait. This has resulted in an international effort to unify the characterization of the mutations, particularly their responsiveness to treatments, and to make the information publicly available through open data repositories. [2]

“Class 1 dysfunction is the result of nonsense, frameshift, or splice-site mutation, which leads to premature termination of the mRNA sequence. This fails to translate the genetic information into a protein product with a subsequent total absence of CFTR protein, and approximately 2% to 5% of cystic fibrosis cases result.

Class 2 dysfunction results in abnormal post-translational processing of the CFTR protein. This stage in protein processing is critical for the protein's correct intracellular transit. As a result, CFTR cannot be relocated to the proper cellular site.

Class 3 dysfunction is characterized by diminished protein activity in response to intracellular signaling. The result is a fully formed protein channel in the cellular membrane that is non-functional.

Class 4 dysfunction is when the protein is produced and correctly localized to the cell surface. However, the rate of chloride ion flow and the duration of channel activation after stimulation is decreased from normal.

Class 5 dysfunction is the net decreased concentration of CFTR channels in the cellular membrane as a result of rapid degradation by cellular processes. It includes mutations that alter the stability of mRNA and others that alter the stability of the mature CFTR protein." [1]

The complexity of the illness is determined by whether or not a molecular deficiency is significant, as well as other variables unrelated to the CFTR protein itself, such as modifier genes or environment.

Chloride conductance mutations are often only mildly severe. Some genotypes exhibit more than one anomaly, trying to add to the complication. Although the major problem caused by the F508 del seriously affected protein folding owing to decreased NBD1 stability, which subjects the protein to proteasome breakdown, the protein also affects CFTR gating and cell surface occupancy duration. Indeed, F508 del is located in a critical region of NBD1 and causes instability. [2]

Additionally, CFTR mutations, non-CFTR gene modifiers, and environmental variables impact illness symptoms and development. Multiple genes that encode apical plasma membrane proteins identified around CFTR, for instance, increase the odds of meconium ileus in babies. Meconium ileus risk loci in solute carrier family members (SLC26A9, SLC9A3, and SLC6A14) are pleiotropic and impact other cystic fibrosis problems in formative years, such as earlier respiratory problems and Pseudomonas aeruginosa invasion at a youthful age. [2]

A significant and continued genome-wide correlation analysis and interconnection study of (3,600 cystic fibrosis patients) found a substantial connection between lung disease severity and loci on (chromosomes 11 and 20). Several analyses from an international twin and sibling research suggest that genetic moderators independent of CFTR account for approximately up to 50percent of the variance in pulmonary function in cystic fibrosis patients, with the balance attributable to environmental agents and random impact. Exposure to environmental variables or toxins (for example, second-hand smoking, pollution, climate, and microbe contact), availability to specialist care, medication adherence, and diversity in medical care have all been proven to impact illness development. [2]

In the subsequent years, the convergence of larger samples, lower costs, and improved processing of huge genetic data are anticipated to offer a better knowledge

of the intricate interactions between CFTR, non-CFTR gene modifiers, and environmental factors on clinical presentations in cystic fibrosis. [2]

Practically, considering all of the above-given evidence will lead to the following knowledge of the disease's pathophysiology. Mutants and other variables can cause reduced chloride secretion and, as a result, greater salt resorption into the cellular space. Higher sodium reabsorption causes increased water resorption, which appears as thicker mucus discharges on epithelial linings and more viscous exocrine secretions. Mucous trapping with obstructive disorders is caused by thickened mucus productions in practically every organ system affected. The sinuses, lungs, pancreas, biliary and hepatic systems, intestines, and sweat glands are the most usually afflicted organs. [1][2]

Sinus illness develops when the consistency of secretion rises, obstructing the sinus Ostia. Further mechanisms are frequently present here. Ciliary dysfunction increased inflammatory mediators, and increased bacterial colonization with infections such as Pseudomonas aeruginosa are among the symptoms. As a consequence of this condition, sinus secretion elimination is hindered. Chronic sinusitis develops as a result, and additional destruction may ensue. [1][2]

Respiratory illness manifests itself as a spectrum blockage caused by thicker mucous production. It is vital to highlight that a cystic fibrosis patient's airways are normal in the womb, during delivery, and after birth. Following infection and the accompanying inflammatory process, the disease develops as a result of a snowball impact. Mucus clogging in the bronchioles leads to the clinical presentation of obstructive pulmonary disease. As a consequence of the blockage, an environment conducive to bacterial development develops within the airways. Bronchiectasis develops, as does thick purulent sputum secretion. [1][2]

The synthesis of neutrophil interleukin-8 from epithelial cells as part of the inflammatory response acts as a secretagogue, boosting mucous secretion and forming a positive feedback loop of mucous secretion with the persistence of inflammation, infection, and structural damage. As a result of this chain, the passageways become obstructed, leading to lung respiratory failings. The primary cause of mortality in cystic fibrosis sufferers is poorly treated respiratory symptoms. [1][2]

Pancreatic complications of cystic fibrosis are caused in significant part by thicker secretions obstructing the pancreatic ductulus. The pancreatic exocrine glands are activated by the transit of stomach contents into the proximal duodenum and secrete pancreatic enzymes into the luminal area of the small bowel. This process is hampered by increased excretion consistency and occlusion of the pancreatic ductulus. Due to the obvious lower sodium bicarbonate content, the net pH of the secretions falls, resulting in much less neutralization of the acidic stomach chyme. Chyme with a lower pH efficiently destroys any pancreatic enzymes that enter the intestinal lumen. As a result, intestinal chyme is not digested enzymatically in the bowels, resulting in pathognomonic oily stools, colicky stomach

discomfort, and nutritional malabsorption from diets. Fat-soluble vitamins A, D, E, and K are particularly low. [1][2]

Moreover, since these enzymes are targeting pancreatic tissues, autodigestion of the pancreas may happen. This causes pancreatitis. When imprisoned pancreatic enzymes begin to degrade the islets of Langerhans, this can lead to endocrine pancreatic failure in serious, persistent instances. The long-term effects of this condition resemble type 1 diabetes mellitus. [1][2]

Similarly, Distal Intestinal Obstruction Syndrome, which is unique to CF, can occur, particularly in individuals with pancreatic insufficiency. This condition is distinguished by ileocecal blockage of inspissated intestinal contents. The biliary and hepatic systems are not spared by increased secretory stickiness. [1][2]

Mucus might clog the biliary ductulus. Obstructive cirrhosis and post-hepatic hyperbilirubinemia are possible complications. As a result of that, elevated hepatic portal vein pressures, esophageal varices, splenomegaly, and hypersplenism may develop. [1][2]

Gallbladder disease is more likely to arise as a part of this picture of cystic fibrosis, with gallstones affecting up to (15percent of persons) with cystic fibrosis. [1][2]

Gastrointestinal inclusion is common in children who have meconium ileus at birth and later develop an intestinal blockage. Meconium ileus is caused by a combination of factors. It is most likely owing to increased fluid consumption as a result of the defective CFTR channel, resulting in dehydration of the gut lumen and constipation, as well as an alteration in luminal contents from normal secondary to pancreatic insufficiency, as stated above. Mechanical blockage causes prolonged inflammation, fibrosis, and stenosis development. Later down the line, this may result in additional intestinal blockage due to fecal impaction or intussusception. [1][2]

Sweat glands differ from all other tissues that have CFTR channels in that the passage of chloride is redirected. Sweat glands typically transport chloride from the outside to the inside zone. As a consequence, salt and water are reabsorbed into the body from sweat gland cells. Failure of the chloride channel to reabsorb chloride, on the other hand, results in salt loss onto the surface of the skin and further fluid loss. This results in the pathognomonic salty skin associated with cystic fibrosis. This can result in hyponatremic dehydration in extended or heated conditions, as well as in more difficult circumstances. [1][2]

There seems to be a chemical mismatch in the circulation attributable to sweat loss, which causes dehydration, arrhythmias, exhaustion, weakness, heatstroke, and, in extreme cases, death. [1][2]

Other associations of CFTR have been postulated in addition to its role as a chloride transport protein. it has been postulated that CFTR is a component of a multiprotein complex at the apical plasma membrane, where three of its amino acids, threonine, arginine, and leucine, serve to anchor the protein to a region known as PDZ-type receptors. These PDZ domains have been

found in a variety of intracellular signaling proteins linked with the plasma membrane. This links CFTR to a variety of different transporters, ion channels, receptors, kinases, phosphatases, signaling molecules, and cytoskeletal components.[1]

These relationships between CFTR and its adhesion molecules play an important role in regulating CFTR-mediated transepithelial ion transport both in vitro and in vivo. These intimate relationships appear to allow CFTR to serve an important role in epithelial cells other than as an ion channel. [1]

Whereas the function of CFTR is not entirely defined, experiments have demonstrated that it is associated with inflammatory reactions, maturational processing, non-chloride ion transport, and intracellular signaling. These other network connections are possible moderators of the cystic fibrosis phenotype and may help explain the considerable variation in clinical severity across people with cystic fibrosis who have comparable genotypes. [1][2]

Diagnosis

The use of newborn screening to make diagnoses is becoming increasingly prevalent. Physicians, on the other hand, should be aware of disease symptoms and signs in older children and adults, therefore we'll go over some clinical manifestations next as a refresher. [2][5]

"Cystic fibrosis newborns may have meconium ileus, persistent neonatal jaundice, or an early lung infection." Failure to grow and poor weight gain, anemia, undescended testicles in boys, recurrent sinopulmonary infections, and a distal intestine obstructive syndrome with or without pancreatic insufficiency can all be symptoms of cystic fibrosis.[2]

The usual age of diagnosis is 6 to 8 months; however, people may not display clinical signs and symptoms until much later. Exacerbations of one or more symptoms are common in adults with CF. [2]

Chronic bronchitis, abnormal pulmonary function tests, bronchiectasis, atypical asthma, allergic bronchopulmonary aspergillosis, and Pseudomonas aeruginosa colonization are all lung symptoms of cystic fibrosis. Chronic rhinosinusitis, chronic post-nasal drip, nasal polyposis, and pan opacification of the paranasal sinuses are all cystic fibrosis sinus symptoms. Pancreatic manifestations include pancreatic insufficiency, recurrent pancreatitis, and early-onset diabetes. Hepatobiliary symptoms include localized biliary cirrhosis, cholelithiasis, periportal fibrosis, liver cirrhosis, portal hypertension, and variceal hemorrhage. [2]

Kyphoscoliosis, osteopenia, osteoporosis, and arthropathy are examples of musculoskeletal manifestations. Iron-deficiency anemia or chronic illness anemia resulting in splenomegaly are examples of hematologic manifestations. Nephrolithiasis, nephrocalcinosis, hyperoxaluria, and hypocitraturia are examples of nephrogenic symptoms. Salty sweat, digital clubbing, and cyanosis are dermatologic symptoms. Acrodermatitis enteropathica caused by zinc insufficiency and scaly dermatitis caused by fatty acid deficit are two more dermatologic diseases caused by malabsorption. [2]

Finally, men may be infertile owing to a lack of vas deferens, whereas females may be infertile due to thicken cervical mucus." [1]

So, if screening may miss some mild cases, such as when the child is born in an area where screening is not routine, the child missed screening despite being born in a screening area, or a laboratory error occurs, we should look at the big picture and combine all available data, facts, and records about cystic fibrosis to make a proper timely diagnosis. [2]

A sweat chloride test is the first step in the diagnostic process. A second sweat chloride test is recommended if the results are normal but you are still experiencing symptoms. If the test results are abnormal, DNA testing is recommended. The initial technique in the diagnosis of cystic fibrosis is the determination of chloride content in sweat.[2]

A chloride level in the sweat of more than 60 mmol/L is deemed pathological, a level of less than 40 mmol/L is considered normal, and a level of 40-60 mmol/L is considered borderline. The sweat test has no diagnostic relevance in infants under the age of seven days or with a bodyweight of less than 3000 g, as well as in patients with edema or eczema. [2]

When evaluating sweat test results, keep in mind that other pathological conditions, such as untreated adrenal insufficiency, ectodermal dysplasia, glycogenosis type 1, hereditary nephrogenic diabetes insipidus, hypothyroidism, hyperparathyroidism, mucopolysaccharidosis, fucosidosis, and severe malnutrition, can all cause borderline or slightly increased chloride rates in sweat. [2]

Sweat test results can indeed be erroneous in cases of pyrexia, dehydration, excessive table salt consumption, and diuretic medication. Sweat tests can identify more than 95 percent of individuals who come with symptoms. The test checks chloride concentration after pilocarpine (a muscarinic receptor agonist) injection, which induces sweat production. yet even after extensive testing, the diagnosis is ambiguous in a small proportion of individuals. Although its diagnostic value is still in its early stages, a modified sweat test that measures adrenergic sweat production has just been developed and may be effective in patients with mild disease.[2]

However, few but definitive cases of cystic fibrosis have been documented using genetic testing, which is an essential element of diagnosis since mutation-specific therapy is becoming more common and can assist to settle unclear cases.[2]

Due to the significant variance in the occurrence of CFTR mutations among ethnic groups, test panels that account for this variation should be employed until whole-exome sequencing is performed. Furthermore, the undetermined importance of the majority of uncommon CFTR mutations does not justify the use of expanded genotyping in patients with ambiguous diagnostic tests. Expanded DNA analysis is recommended if one or fewer CFTR mutations are discovered. The discovery of two CF-related mutations, on the other hand, validates the diagnosis of cystic fibrosis. [2]

Today, DNA analysis is a cutting-edge diagnostic tool for cystic fibrosis. However, because most laboratories can only identify the most common mutations, genetic confirmation of uncommon variations of the illness is likely to go undiscovered.

Also, Lung function assessments, imaging mostly high-resolution CT, MRI is becoming more popular, and bronchoalveolar lavage is now performed to diagnose lung disease.

Bronchoalveolar lavage usually reveals a high number of neutrophils, and microbiology is frequently positive for Haemophilus influenza, Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia, Escherichia coli, or Klebsiella pneumonia.[2]

Pulmonary function testing is an important method for assessing and monitoring the disease status and progression in cystic fibrosis. The most frequent pulmonary function test is spirometry. It quantifies the amount of air released during a full and vigorous expiration following a peak inhale. The most essential variables given are the total exhaled volume, known as the forced vital capacity (FVC), the volume expelled in the first second, known as the forced expiratory volume in one second (FEV1), and their ratio (FEV1/FVC). [2]

These numbers provide an interpretation of the lung ventilation function's state. To obtain an anticipated normal value, these data are compared to an expected normal for age, height, and gender. The measured value is then expressed as a percentage of normal, where normal = 100%. A normal or high FEV1 and/or a low FVC might be signs of restrictive lung disease.[2]

A low FEV1 combined with a high FVC suggests obstructive lung disease with airway trapping. Cystic fibrosis is characterized by air trapping patterns and poor FEV1 levels that are related to the severity of the disease. [2]

The transepithelial potential difference measurement is an additional diagnostic test that is only accessible in a few specialist locations. In vivo techniques typically include measuring the potential difference across the nasal or respiratory epithelium with a catheter connected to a peripheral electrode. Rectal potential difference can be determined in vivo; alternatively, CFTR activity on excised rectal biopsy tissue can be assessed in vitro using open-circuit or closed-circuit currents. [2]

Other in vitro approaches for evaluating CFTR activity, such as intestinal organoid swelling or the function of nasal epithelial cells maintained in culture, are also gaining popularity. [2]

When compared to healthy controls, the nasal potential difference test in cystic fibrosis patients has many key characteristics, including a raised potential difference at baseline, a heightened reaction to amiloride, and a lowered response to chloride-free isoproterenol. [2]

A chest radiograph can aid in the diagnosis of hyperinflation, bronchiectasis, abscesses, and atelectasis. Pan opacification of the paranasal sinuses may be seen on sinus radiography. In newborns with meconium ileus, abdominal radiology may be useful.[2]

The immunoreactive trypsinogen (IRT) test, which detects a pancreatic enzyme, improves sensitivity and specificity in neonates with

meconium ileus. IRT monitoring can be linked to the severity of CF, and when it falls below detectable levels, it may signal the need to begin pancreatic enzyme replacement. Depending on the presenting symptoms, further tests may be required. [2][5]

Other supporting tests, such as stool human fecal elastase measurement for pancreatic insufficiency and, in post-pubertal males, semen analysis to screen for azoospermia, might be considered to clarify the diagnosis. [2]

Diagnosis is hampered in individuals with positive diagnostic tests but no symptoms, as well as in people with a cystic fibrosis phenotype but negative or inconclusive diagnostic testing. The situation for the latter patients is pretty easy; regardless of the underlying diagnosis, every organ illness should be treated on its own merits, and the patient should be closely watched. [2]

Patients who appear to be symptom-free but have positive diagnostic tests should be closely monitored to detect the development of problems without overburdening the patients with therapy. [2]

Screening

Programs for newborn screening lower illness severity, the difficulty of caring, and the expense of treatment. They also prevent dropping or delayed diagnosis. "In the United States, babies are checked for cystic fibrosis as part of a routine newborn screening panel. Prenatal ultrasonography may reveal meconium peritonitis, intestinal dilatation, or the absence of a gallbladder in some instances of CF. Such discoveries frequently result in prenatal cystic fibrosis carrier screening." Several techniques are employed, including immunoreactive trypsinogen (IRT) screening in conjunction with DNA molecular analysis, double IRT testing, and pancreatitis-associated protein (PAP) testing. The approach utilized is determined by geographical, ethnic, and economic factors, and nations should do independent research to determine the most appropriate strategy that matches local demands.[2][5]

(IRT) testing is usually followed by testing for a panel of common cystic fibrosis mutations has been the standard in most programs. similarly, A heel prick is used to collect blood samples immediately after delivery. As a last diagnostic test, a sweat test should be performed.[2][5]

Appropriate assistance for families of recently diagnosed babies, as well as referral to a cystic fibrosis care center, are key components of so programs. Screening has revealed several kids with unexplained diagnoses, a positive (IRT) test, one or no identifiable mutations, and an average sweat chloride content of (30–60 mmol/L). These children should be thoroughly examined and observed because, while they may be asymptomatic in their early years, some will develop a cystic fibrosis phenotype as they get older. These people typically have mutations that are linked to the CFTR protein's residual function. Cystic fibrosis metabolic syndrome is the name given to this kind in the United States.[2][5]

Importantly, Early detection of lung illness Infants identified through screening are frequently asymptomatic, with little or no clinical symptoms of lung illness. It is critical

not to miss key warning signals or generate worry by overinterpreting minor irregularities while evaluating these infants.[2][5]

Treatment options

Cystic fibrosis is a systemic disease that, if left untreated, has far-reaching consequences for both quality and quantity of life. As a result, treatment should concentrate on restoring function to minimize acute sickness occurrences.[2]

Preserving pulmonary function should be prioritized by aggressively treating respiratory infections and clearing mucus from airways, maximizing nutritional status using pancreatic enzyme supplements and multivitamins, and addressing any other health concerns that may occur.[2]

As previously indicated, the most prevalent cause of death in cystic fibrosis is a pulmonary illness. As a result, it is critical to have low diagnostic and intervention criteria in pulmonary sickness exacerbations. A pulmonary exacerbation is a deterioration in lung function caused by an illness. Shortness of breath, tiredness, active cough, and fever are common symptoms. During an exacerbation, pulmonary function tests will deteriorate from baseline. Any severe sickness should necessitate admission to a hospital that is well-versed in cystic fibrosis care. The treatment of pulmonary sickness should focus on the following basic goals: treating the infection and improving oxygenation.[2]

P. aeruginosa is known to cause infectious etiologies, and antibiotic treatment should be broad-spectrum against this bacterium. However, a sputum culture and sensitivity profile for the pathogens present should be acquired. According to cystic fibrosis recommendations, each pathogenic bacterium cultivated from respiratory secretions should be treated with at least one antibiotic, and P. aeruginosa infections should be treated with two antibiotics. Mild exacerbations may respond to oral antibiotics, while severe exacerbations need intravenous therapy. When an intravenous option is available, inhaled antibiotics are not indicated.[1][2][7]

Antibiotics inhalation in patients with chronic P. aeruginosa infection, nebulized tobramycin which is an aminoglycoside antibiotic improved lung function, decreased exacerbations, and raised weight. A dry powder formulation of tobramycin that reduces delivery time has recently been found to have equivalent effectiveness and increase patient satisfaction.[2][7]

Inhaled aztreonam which is a beta-lactam antibiotic has also been demonstrated to be effective when compared to both placebo and inhaled tobramycin. Other antibiotics, such as colistin, are used in some areas, and various other inhalation antibiotic formulations are being researched.[7]

Few studies have looked at the role of inhaled antibiotics for various bacterial infections that are frequent in cystic fibrosis patients. Several randomized controlled studies have indicated that P. aeruginosa-infected individuals treated with azithromycin have improved lung function,

quality of life, weight, and time to next exacerbation.[2][7]

Macrolides' mode of action in cystic fibrosis may be anti-inflammatory rather than antibacterial. When individuals lacking P. aeruginosa were given azithromycin, there was no improvement in lung function, although there was evidence of a lower risk of pulmonary exacerbation. Single-center research found an increase in the frequency of nontuberculous mycobacteria, raising questions about whether long-term azithromycin therapy is a contributing cause. A second national data registry study did not support this conclusion, although the effect of macrolides on nontuberculous mycobacterial infection remains debatable because full case estimation is rare in registry analysis.[2][7]

Anti-inflammatory medications, such as glucocorticoids, are also utilized to help expand the airways and alleviate the blockage. Several anti-inflammatory medications, including oral corticosteroids, inhaled corticosteroids, and nonsteroidal anti-inflammatory medicines like ibuprofen, and leukotriene inhibitors, have been explored in cystic fibrosis patients. Whilst ibuprofen slowed the pace of deterioration in lung function, particularly in younger patients and adolescents, its usage has been limited due to the necessity to monitor blood levels to maximize the effect.[1][2]

Oral steroids have negative side effects, while inhaled steroids have a limited impact on people who do not have asthma as well as cystic fibrosis. [1][2]

A leukotriene B4 inhibitor known as BIIL 284 was linked to greater exacerbations and resulted in the early conclusion of one trial, highlighting concerns that anti-inflammatory medicines must strike a fine balance between lowering inflammation and impairing the patient's response to infection. [1][2]

Mucolytic and hydrator treatments are available. Dornase alfa, a recombinant human deoxyribonuclease, degrades DNA produced by decomposing neutrophils that collect in the airways of cystic fibrosis patients, lowering the viscosity of airway secretions and resulting in better lung function and fewer exacerbations. [1][2]

The first large-scale research demonstrating the benefit of nebulized dornase alfa was published more than 20 years ago. Benefits have since been demonstrated in individuals with advanced lung illness (FEV1) as well as in younger patients with moderate disease. In kids under the age of five, this treatment is considered standard of care. [1][2]

In a randomized controlled experiment, hypertonic saline was demonstrated to enhance lung function and minimize exacerbations by acting as a hydrating agent and increasing mucociliary clearance. A decrease in exacerbations was not detected in a trial of children aged 4 months to 5 years, however, sub-studies on lung function showed beneficial results. [1][2]

Additional research into the effectiveness of hypertonic saline in younger children is now underway. Inhaled dry powder mannitol is another osmotic agent that has been found in two studies to enhance lung function; the results have been more consistent in adults than in children.[2]

The task of breathing should be optimized, with nasal cannula oxygen used when necessary. Bilevel positive airway pressure (BiPAP) breathing may be required to overcome airway entrapment. [2]

Intubation with mechanical ventilation is a possibility, although it should be prevented wherever feasible and done only when respiratory collapse is inevitable. Inhaled bronchodilators such as albuterol and ipratropium bromide should be used to help with respiration and oxygenation. In combination with chest physiotherapy, agents such as inhaled dornase alfa or inhaled hypertonic saline are recommended to enhance airway secretion evacuation. [2]

Despite significant advances in cystic fibrosis medication therapy, the disease process continues, and without surgical intervention, the lungs will eventually collapse prematurely from the disease load. [2]

Lung transplantation is the preferred or the standard therapy for end-stage lung illness. The prognosis for transplant patients has significantly improved, and median survival now approaches or surpasses 10 years in many facilities. The transplant's timing is complex. [2]

The International Society of Heart and Lung Transplantation issued a list of criteria to consider when contemplating transplant referral, which takes into account a 5-year expected survival of less than 50%. the FEV1 has dropped to 30% of expected values, dropping rapidly FEV1 despite ideal therapy, a 6-minute walk distance of fewer than 400 meters, the development of pulmonary hypertension in the absence of a hypoxemic exacerbation, clinical decline characterized by an increasing frequency of exacerbations, including acute respiratory failure requiring non-invasive ventilation, a pattern of poor clinical recovery from successive exacerbations, deteriorating nutrition. [2]

Almost all cystic fibrosis lung transplants will necessitate the replacement of both lungs. This is since a sick native lung would serve as a source of contaminated secretions, endangering the transplanted lung and possibly causing respiratory failure. It is crucial to highlight that transplantation is not a cure for CF, although it does extend the life and provide considerable symptom alleviation. [2]

Timely referral and close contact between cystic fibrosis and transplant facilities are necessary to provide adequate time for assessment of appropriateness, determining if criteria are satisfied, and establishing that no predicted contraindications exist. Donor allocation protocols differ from country to country, but the goal is to prioritize people waiting for transplants who have the most restricted pre-transplant survival. [2]

Adjunctive therapy, such as non-invasive ventilation, can serve as a stopgap until transplantation is possible. Bronchiolitis obliterans, which is assumed to be a kind of chronic allograft rejection, is the most prevalent cause of graft failure.[2]

To compensate for malabsorption, people with cystic fibrosis are recommended to eat a high-fat diet supplemented with fat-soluble vitamins. Furthermore, individuals with cystic fibrosis are recommended to follow a high-calorie diet to maintain a healthy weight and combat the chronic inflammation and recurrent infections that are typical. [2]

Women should take 2500 to 3000 calories per day, while males should consume 3000 to 3700 calories per day, according to the Cystic Fibrosis Foundation. Those who live in hot environments or engage in activities that produce perspiration are urged to consume more salt in their diet. Oral feedings are recommended; nonetheless, enteral feedings should be explored if the intake does not match metabolic requirements as measured by continuous declines in BMI. [2]

Commonly, these take the form of gastric tube feedings or jejunal tube feedings. Multiple control trials of enteral nutrition in people with cystic fibrosis have shown rewards in the form of enhanced or neutral lung function following exacerbations of a disease that correlate directly with BMI. [2]

Having said that, no randomized trials of enteral nutrition in cystic fibrosis patients have been conducted yet. Only when oral or enteral feeding fails to satisfy metabolic demands should parenteral nutrition be explored. Parenteral feeding has been associated with an increase in the risk of sepsis episodes and should be taken with caution. [2]

Regular exercise is recommended for cystic fibrosis patients to maintain and support lung function.[2]

Treatment of the basic problem in concepts of treating the underlying genetic defect, therapies that target CFTR dysfunction work by inserting a normal copy of CFTR into patients' cells (gene therapy), improving CFTR expression on the cell surface, ramping up the 'opening probability' of existing channels, or trying to target other ion channels to recompense for its impairment.[2]

To reduce systemic toxicity, somatic gene therapy has mostly been researched as a topical treatment applied to the airways. As demonstrated in cell cultures and animals, the approach allows for the temporary production of mature and functioning CFTR.[2]

Because of their high transfection effectiveness, adenoviral vectors were originally employed in human experiments. At modest levels, single-dose experiments including nasal or intratracheal injection revealed transitory expression of CFTR with no significant deleterious effects. Nonetheless, repeated dosage induces an immunological response that lowers transfection efficiency, and no therapeutic efficacy has been seen. [2]

Modifications may aid in lowering their immunogenic potential. Adeno-associated virus vectors are less immunogenic than adenoviral vectors, and preliminary investigations indicate sustained expression and good trends in clinical outcome indicators. Nevertheless, this conclusion was not confirmed in a longer-term multi-dose experiment. Lentiviral vectors are now being studied in preclinical research, where they have demonstrated great transfection efficiency and extended CFTR expression activity. Liposomal vectors may be able to overcome the constraints of viral vectors. Liposomes are less immunogenic and hence more suited for repeated dosage; nevertheless, this advantage is accompanied by a lower degree of transfection efficiency. [1][2]

The UK Cystic Fibrosis Gene Therapy Consortium just finished a multi-center multiple-dose experiment, and results are expected soon. Another technique being investigated is the delivery of RNA rather than DNA. Therapy based on translational readthrough. Premature termination codons (PTCs), which result in shortened proteins, and mRNA transcripts that suffer nonsense-mediated degradation are examples of Class I mutations. [2]

Aminoglycosides, such as gentamicin, can attach to the ribosome and allow PTC readthrough, resulting in some full-length protein synthesis and partial channel function restoration. Both in vitro and topical experiments on the nasal epithelium in patients with halt mutations on at least one allele have demonstrated indications of CFTR expression following gentamicin therapy. The clinical usefulness is restricted since gentamicin must be administered for an extended period, which would almost certainly result in renal and/or ototoxicity.[2]

Ataluren was created as a molecule with similar translational readthrough capabilities but without the possible side effects associated with aminoglycosides. Although first uncontrolled investigations in patients revealed an improvement in chloride conductance as evaluated by nasal potential difference, a larger placebo-controlled experiment failed to demonstrate therapeutic benefit. However, the subgroup of patients who did not get inhaled antibiotics and did not have persistent exposure had reduced lung function reduction after 12 months, which might be explained by competitive inhibition at the ribosome level. [2]

One research is now underway to assess effectiveness in this subgroup prospectively. Overall, the effects seen thus far are modest, but they might be amplified by combining ataluren with a CFTR potentiator.[2][3][9]

potentiators Drugs that improve the frequency of channel opening may be effective against mutations that produce residual surface expression. The first of these medications, ivacaftor, has been licensed in most countries for clinical usage in patients with class III mutations. The most frequent CFTR class III mutation, G551D, is linked with normal cell surface expression but decreased gating.[2][3][9]

Ivacaftor enhances CFTR function, as evidenced by improvements in ion channel measurements. Notably, sweat chloride concentrations decreased below the diagnostic threshold in the majority of treated individuals, a finding that was validated in an observational analysis. This decrease in sweat chloride is associated with a significant increase in lung function as well as improvements in other clinical variables such as weight, symptoms, and pulmonary exacerbations.[2] [3][9]

Similar effects have been reported. Similar results have been reported in additional gating variants, highlighting the possibility of CFTR medication in a wider variety of CFTR mutations. Other mutation classes that potentially benefit from CFTR function potentiation are also being studied, including class IV and class V mutations, as well as class VI mutations linked with residual CFTR function. Furthermore, because readthrough and corrector treatment is unlikely to restore CFTR function on their own, potentiators

may be required for combination therapy in individuals with class I or class II mutations. [2][3][9]

Potentiation of CFTR activity may potentially be beneficial in conditions characterized by secondary CFTR dysfunction, such as chronic bronchitis because smoke exposure has been linked to secondary CFTR dysfunction.[2][3][9]

F508del, the most frequent CFTR mutation, is related to poor protein folding, resulting in proteasomal breakdown with little or no CFTR reaching the apical membrane. Indeed, because F508del homozygous individuals have little or no CFTR expression on the cell surface, potentiators like ivacaftor have no effect on chloride transport in bronchial epithelial cells; this discovery was recently verified in Phase II research.[2][3][9]

Drugs that impact CFTR transport have been dubbed correctors, even though they do not necessarily correct the folding fault. Although certain correctors interfere with cell chaperones and other quality control processes, their usage often enhances trafficking to the cell surface.[2][3][9]

The most well-studied compounds have emerged from high-throughput screening procedures, with two small molecules, lumacaftor and VX-661, undergoing clinical trials. Both medications show no therapeutic effect when used alone in individuals with F508del; in fact, lumacaftor alone reduced lung function. When ivacaftor was combined with lumacaftor, lung function improved above baseline. The extent of the impact was much less than that reported in individuals with the G551D mutation (class III) in response to ivacaftor alone, corroborating results from tests in human bronchial epithelial cells. Recent in vitro data suggest that ivacaftor-mediated CFTR activation may destabilize F508del CFTR and reduce the beneficial effects of some correctors, including lumacaftor; whether this finding is relevant is unclear, but this interaction could explain why combination therapy with ivacaftor and lumacaftor has a relatively small clinical effect in F508del homozygous patients. [2][3][9]

Even though the clinical effectiveness evidence for combination treatment is encouraging, it is obvious that the quest for more CFTR corrector drugs must continue. By targeting unique cellular pathways, adding a second corrector has been demonstrated to boost the effectiveness of lumacaftor and ivacaftor in vitro.[2][3]

Therapy is based on ion channels. Cystic fibrosis is related to reduced CFTR chloride and bicarbonate secretion and increased ENaC salt absorption. Targeting additional apical ion channels is another potential approach for addressing the ion imbalance on the epithelial membrane. The P2Y purinoceptor agonist denufosol was used to study the activation of the apical calcium-activated chloride channel using derivatives of its natural activator ATP. [2]

Although first research showed some promise, further investigations failed to corroborate the positive impacts. The use of amiloride to inhibit salt absorption was first investigated, but clinical effectiveness was found to be limited. Stronger and selective inhibitors with longer half-lives are being developed at the moment.[2]

Treatment outlook

Understanding the underlying genetic abnormalities and the mechanisms by which CFTR mutations cause disease has resulted in CFTR-specific therapies that are either already accessible or on the verge of entering clinical trials.

Additional compounds are being evaluated in ongoing studies, so the arsenal of treatment options is likely to grow. Although genotype-specific medication is referred to be personalized medicine, it will not help each patient in the very same way. Some studies have already revealed that responsiveness to therapies varies even among patients with the same CFTR mutation. Exploring modifier genes of implicated intracellular pathways or other ion channels may aid in a better understanding of this variability and the identification of other therapeutic targets.[2]

Furthermore, present investigations are limited to individuals with CFTR mutations that have established functional repercussions for CFTR processing and function, and will not apply to patients with uncommon mutations.[2]

Individualized treatment plans will most likely be required for CFTR-directed medication, especially for individuals with uncommon or difficult-to-treat alleles. Individualized therapy will necessitate the use of test systems or biomarkers with great precision in estimating treatment response. Cells obtained from patients might be employed in experiments to examine the most promising therapy combination in vitro. [2]

Nasal epithelial cells and intestinal cells converted into organoids are now being explored as promising models due to their availability. Preliminary studies employing stem cells obtained from skin fibroblasts or blood cells turned into airway epithelial cells may provide an option in shortly the near future. Modifications or enhancements to these in vitro tests might be tested topically in vivo by administering them to the sweat gland or nasal epithelium.[2]

Furthermore, sensitive clinical outcome indicators will need to be established to allow individual patient tracking of medication response. CFTR-directed therapy should eventually avoid lung damage; however, this will necessitate treatment early in the disease process, ideally as soon as the diagnosis is made. [2]

Newborn screening gives us a chance, but more work needs to be done to develop meaningful outcomes in young children to give evidence for the efficacy of early treatment approaches. Clinical studies in this age range will most likely need to focus on preventing progression rather than improving disease symptoms. If this is accomplished, CFTR regulation may be able to sustain lung health while also preserving lung function and structure. [2][5]

Furthermore, early use of CFTR modulators may influence other disease presentations, such as exocrine and endocrine pancreas function. In individuals with advanced illness, however, the best situation may be to convert cystic fibrosis to non-cystic fibrosis bronchiectasis, a condition that is far less severe but typically still progressing. [2]

Hence, albeit with effective CFTR-directed medication, it will be decades before patients no longer require treatment for the predominant disease symptoms of mucus blockage, infection, and inflammation. Although targeting CFTR is anticipated to make a significant effect, developing improved therapy options for these components of the illness will remain critical in maintaining lung health in cystic fibrosis patients.[2]

Conclusion

CF is a rather uncommon multi-systemic autosomal recessive disorder. Aside from genetics, the outcome of the condition is largely controlled by a variety of other variables, including the quality of respiratory issues prevention and treatment, the amount of air pollution, the patient's nutritional state, and others. Although in most situations, this is a serious and sometimes fatal condition, the life outlook of such individuals has improved in recent years due to advancements in healthcare and collaboration therapy. So. In my opinion and as an analytic study for the pieces of information already mentioned above, my conclusion is as follow.

CF necessitates a combined treatment strategy in specialist CF clinics, encompassing much suitable equipment for a better patient's quality of health in the form of appropriate and well-balanced non-pharmacological and pharmacological therapy. Furthermore, substantial large-scale clinical studies are required to identify drugs that target the most frequent types of CFTR.

References

1. Yu E, Sharma S. Cystic Fibrosis. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493206/

2. Ratjen, F., Bell, S., Rowe, S. et al. Cystic fibrosis. Nat Rev Dis Primers 1, 15010 (2015). https://doi.org/10.1038/nrdp.2015.10

3. Radlović N. Cystic fibrosis. Srp Arh Celok Lek. 2012 Mar-Apr;140(3-4):244-9. PMID: 22650116. https://pubmed.ncbi.nlm.nih.gov/22650116/

4. Rafeeq, M.M., Murad, H.A.S. Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med 15, 84 (2017). https://doi.org/10.1186/s12967-017-1193-9

5. Elborn JS. Cystic fibrosis. Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29. PMID: 27140670. https://pubmed.ncbi.nlm.nih.gov/27140670/

6. Sellers ZM. Pancreatic complications in children with cystic fibrosis. Curr Opin Pediatr. 2020 Oct;32(5):661-667. doi: 10.1097/MOP.0000000000000934. PMID: 32773577; PMCID: PMC7769036.

https://pubmed.ncbi.nlm.nih.gov/32773577/

7. Goss CH. Acute Pulmonary Exacerbations in Cystic Fibrosis. Semin Respir Crit Care Med. 2019 Dec;40(6):792-803. doi: 10.1055/s-0039-1697975. Epub 2019 Oct 28. PMID: 31659730; PMCID: PMC7528649. https://pubmed.ncbi.nlm.nih.gov/31659730/

8. VanDevanter DR, Kahle JS, O'Sullivan AK, Sikirica S, Hodgkins PS. Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment. J Cyst Fibros. 2016 Mar;15(2):147-57. doi: 10.1016/j.jcf.2015.09.008. Epub 2015 Oct 9. PMID: 26454351. https://pubmed.ncbi.nlm.nih.gov/26454351/

9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Cystic Fibrosis Agents. [Updated 2021 Aug 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547889/

10. Klimova Blanka, Kuca Kamil, Novotny Michal, and Maresova Petra, Cystic Fibrosis Revisited – a Review Study, Medicinal Chemistry 2017; 13(2). https://dx.doi.org/10.2174/1573406412666160608113235

11. Cutting, G. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 16, 45–56 (2015). https://doi.org/10.1038/nrg3849